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THE PROBLEM: WHY IS ALZHEIMER’S DISEASE SO SEVERE AND 
PROGRESSIVE? 
 
DEMENTIA: A DEFINITION 
 
While it is common to label memory loss as the primary symptom of dementia, memory 
functioning only accounts for one the many factors associated with a dementia diagnosis (Hugo, 
2014).  Dementia symptoms also involve impairment in regard to attention, executive 
functioning, learning, language, and visuo-spatial abilities (Hugo & Ganguli, 2014).  Thus, 
dementia is characterized by a clinically significant and severe cognitive impairment, affecting a 
patient’s functionality in many different ways (Lane et al., 2018).  While some cognitive 
impairment is not unusual with aging, clinicians agree that the impairment experienced in 
dementia patients affects multiple cognitive areas and must impede daily functioning, even 
socially (Hugo & Ganguli, 2014).  Of course, the shift from normal cognitive functioning to a 
severe level of cognitive impairment occurs on a spectrum; in fact, the most recent edition of the 
Diagnostic and Statistical Manual of Mental Disorders includes a separate diagnosis for the 
intermediate state of cognitive decline, Mild Cognitive Impairment (MCI) (Chagas et al., 2018).  
These patients do not display the functional impediments seen in true dementia patients 
(Karantzoulis et al, 2011).  
Strict guidelines and testing strategies are also being developed to ensure accurate 
diagnosis and proper indication of significant changes in the severity of symptoms, most often 
initiated by a demonstrated concern by the patient or the patient’s loved ones (Albert et al., 
2011). However, it must be noted that the cognitive tests used to assess cognitive status are not 
very reliable, with results varying based on the presence of external factors affecting baseline 
conditions (Albert et al., 2011).  Age is a particular variable of interest, as scores on generalized 
cognitive tests may be skewed for the elderly at baseline (Albert et al., 2011).  This highlights an 
obstacle neurologists face when evaluating any neurological or psychiatric disorder, as a 
patient’s presentation rarely warrants a textbook diagnosis; for this reason, treatment and 
research in these fields is quite complex.  Additionally, dementia and MCI can be caused by 
trauma and other external factors, and the pathology of dementia is often comorbid with 
conditions like cardiovascular disease, so the underlying causes of dementia are also often 
difficult to determine (Albert et al., 2011).  Early detection of dementia is necessary for effective 
treatment; unfortunately, due to these discrepancies, there are many cases where symptoms of 
cognitive impairment are overlooked and, therefore, undiagnosed (Atri, 2019).  In fact, a study 
showed that primary care physicians ignored early onset symptoms in two thirds of dementia 
patients (Valcour et al., 2000).  The complicated nature of the disease is thus made even further 
complex due to poor recognition of symptoms during such a critical period of potential 
treatment.   
 There are several types of dementia, each with different etiology, affecting different 
domains of cognitive impairment (Dening & Sandilyan, 2015).  Vascular dementia, also called 
vascular cognitive impairment, is an extremely common form of dementia, second only to 
Alzheimer’s Disease (O’Brien & Thomas, 2015).  As the name implies, this form of dementia is 
characterized by poor blood circulation to the brain (Dening & Sandilyan, 2015).  There are 
many underlying risk factors for vascular dementia such as cardiovascular disease, hypertension, 
and stroke.  Importantly, post-stroke dementia is actually only one of the subtypes of vascular 
dementia as there are many cases of vascular dementia that present without history of stroke 
(O’Brien & Thomas, 2015).  Patients typically exhibit impairment in language, memory, 
executive functioning and attention; however, as there are many variants of vascular dementia, 
presentation can vary and therefore, diagnosis and treatment are challenging (O’Brien & 
Thomas, 2015).  The third most prevalent form of dementia is Lewy Body dementia, 
characterized by the presence of alpha-synuclein protein aggregates, also known as Lewy 
Bodies, in the brain (Dening & Sandilyan, 2015).  With many similarities to Parkinson’s Disease, 
patients may exhibit symptoms such as trembling of extremities and a shuffled gait pattern 
(Dening & Sandilyan, 2015).  Other symptoms include disturbed sleep, visual hallucinations, 
memory loss, visuospatial difficulty, and impaired executive function (Dening & Sandilyan, 
2015).  While dementia is often a late complication of Parkinson’s Disease, the two are 
considered distinct disorders (Garcia-Ptacek & Kramberger, 2016).   Frontotemporal dementia, a 
much less common form of dementia, is a label given to dementias that affect the rostral portion 
of the brain (Dening & Sandilyan, 2015).  Unlike other forms of dementia, the onset of 
frontotemporal dementia can occur as early as ages 30-40 (Olney et al., 2017).  Subcategories 
include behavioral variant frontotemporal dementia, categorized by profound behavior changes, 
and primary progressive aphasia, demonstrated by significant language and speech impairment 
(Dening & Sandilyan, 2015).  These categories of dementia are not firmly defined, and there is 
some overlap in pathology, especially between vascular dementia and Alzheimer’s Disease, 
which are often comorbid (O’Brien & Thomas, 2015).  In fact, when more than one form of 
dementia is present, a patient is given a diagnosis of Mixed Dementia (Dening & Sandilyan, 
2015). Additionally, there are other forms of progressive dementia that do not fit into these 
categories, including Multiple Sclerosis, Creutzfeld-Jakob disease, and Huntington’s Disease 
(Dening & Sandilyan, 2015). 
Essentially, there are many types of dementia that overlap, indicating the complex 
mechanisms underlying the development and progression of these diseases, especially 
considering the presence of comorbid disorders and many risk factors involved.  Genetics also 
plays an integral role in each dementia diagnosis, each to a varying degree; for example, 
Huntington’s Disease is grossly hereditary, while certain biomarkers may only suggest that an 
individual is more susceptible to developing Alzheimer’s Disease (Dening & Sandilyan, 2015).  
Most importantly, the prevalence of dementia is increasing on a global scale, and researchers 
expect that there will be 115.4 million people diagnosed with dementia in 2050 (Hugo & 
Ganguli, 2014). Thus, continued research and the development of innovative treatment plans is 
imperative for the future of dementia disorders.   
 
ALZHEIMER’S DISEASE: A GENERAL OVERVIEW  
 By far, Alzheimer’s Disease (AD) accounts for the majority of dementia cases, affecting 
approximately 70% of dementia patients over the age of 65 (Ljubenkov & Geschwind, 2016, 
2016).  The disease almost exclusively affects elderly individuals, as the prevalence AD cases 
doubles every five years after age sixty-five (Lane et al., 2018).  In addition, females are about 
1.5 times more likely to develop Alzheimer’s Disease compared to males (Atri, 2019).  From a 
biological perspective, Alzheimer’s Disease is associated with abnormalities in the function of 
multiple different classes of neurotransmitters, indicating the complex brain mechanisms 
involved in the pathology of the disease (Selkoe, 1991).  In terms of symptoms, a diagnosis of 
AD is preceded by a diagnosis of MCI, and patients commonly demonstrate impaired episodic 
memory, spatial orientation, language abilities, and executive functioning (Karantzoulis et al., 
2011).  Eventually, patients experience a more progressive and comprehensive cognitive decline, 
which results in extreme difficulty with multitasking and completing daily tasks.  
In addition, there are fundamental structural abnormalities in the brain that characterize 
degeneration of brain tissue seen in AD, including the presence and accumulation of β-amyloid 
plaques (Selkoe, 1991).  As supported by the Amyloid Hypothesis, this pathology is widely 
considered as one of the primary causes of the impaired function of neurotransmitters, cognitive 
dysfunction, and the disruptions of homeostasis that characterize AD (Hardy & Selkoe, 2002).  
Along with the discovery of an accumulation of neurofibrillary tangles of tau proteins, these 
factors have since been used as biomarkers for identifying early-onset Alzheimer’s Disease and 
differentiating AD from other forms of dementia or cognitive impairment (Hardy & Selkoe, 
2002).  However, the mechanisms underlying the presence of these of β-amyloid plaques and tau 
proteins are still being investigated and the origins of this pathology are still unclear (Lane et al., 
2018).  As a result, the true relationship between these biomarkers and the cognitive changes 
seen in AD is unknown (Ferreira-Vieira et al., 2016).  Nonetheless, the contribution of the 
discovery of these biomarkers to diagnosis of AD has also proven to be very effective for 
determining progression of the disease (Lane et al., 2018).   
 Another biological characteristic of AD is the dysfunction of the cholinergic system in 
the brain, which is an important component of cognition, affecting neural plasticity as well as 
learning and memory (Hampel et al., 2018).  There are multiple cholinergic pathways in the 
brain, but scientists have discovered that the main area of cholinergic degeneration in AD is the 
nucleus basalis of Meynert, which is located in the basal forebrain (Hampel et al, 2018).  
Acetylcholine receptors, categorized as either muscarinic or nicotinic, function in multiple areas 
of the brain and are very important for cognitive functioning, response to stress, attention, and 
the sleep-wake cycle (Ferreira-Vieira et al., 2016).  Muscarinic receptors, labeled M1-M5, are 
involved in many complex signaling cascades that affect the regulation of proteins in brain areas 
affected by AD, including the hippocampus, prefrontal cortex, and thalamus (Ahmed et al., 
2017).  Amyloid precursor proteins are under regulatory control of the cholinergic system, so 
researchers have speculated that fluctuations of the cholinergic neurons lead to dysregulation of 
proteins in the brain and, potentially, the cognitive impairments seen in AD (Ahmed et al., 2017).  
Treatment methods using cholinesterase inhibitors are very effective and are a widely used 
treatment method for the symptoms of Alzheimer’s Disease (Hugo & Ganguli, 2014). However, 
I argue that behavioral methods may be more effective for long-term improvement and recovery 
from AD-associated neuronal cell death in the cholinergic system.   
A diagnosis of Alzheimer’s Disease warrants brain imaging, as AD patients commonly 
present with bilateral symmetrical atrophy to medial brain regions in the temporal lobes (Lane et 
al., 2018).  Extensions of this atrophy are presented in later stages of the disease (Karantzoulis et 
al., 2011).  In addition, imaging allows clinicians to rule out other potential causes of cognitive 
impairment, such as lesions to brain regions as well as other possible neurological disorders 
(Lane et al., 2018).  Genetic testing is also effective, as a family history of AD has been linked to 
about seventy percent of the risk of developing the disease (Lane et al., 2018).     
 
WHY STUDY ALZHEIMER’S DISEASE? 
Alzheimer’s Disease is recognized as one of the top ten leading causes of death for the 
United States; however, the CDC has released data showing that establishing death rates for 
Alzheimer’s Disease is challenging because the death of many AD patients is frequently 
attributed to complications that arise from the disease, such as decreased mobility, dysphagia, or 
malnutrition that increase their susceptibility to serious infections such as pneumonia 
(Alzheimer’s Association, 2016).  In fact, Medicare released data demonstrating that 
approximately one third of the annual deaths of Americans older than age 65 have a medical 
history of dementia (Alzheimer’s Association, 2016).  Thus, the progression of Alzheimer’s 
Disease is an extremely relevant factor in regard to health complications and, unfortunately, even 
death of AD patients.  
 Public health systems around the world are not equipped to handle the pervasiveness of 
Alzheimer’s Disease in terms of seeking out a cure as well as treating a perpetually increasing 
number of patients annually (Wortmann, 2012).  With such high prevalence, AD has become an 
economic issue as a result of healthcare costs and the loss of members of the workforce due to 
caregiver necessity (Wortmann, 2012).  The World Health Organization highlights that this 
public health problem stems from the stigma associated with it, also reflective of how 
socioeconomic status may impact the way patients, families, and practitioners approach and 
ultimately endure the progression of AD (World Health Organization, 2012).  It is clear that AD 
has made an extreme impact on healthcare, emphasized by the continued challenges researchers 
face in determining its etiology, developing effective treatment plans, and ultimately finding a 
cure.  Alzheimer’s Disease differentially affects all parties involved, and, with such social value, 
















A POTENTIAL SOLUTION: THE ROLE OF THE CIRCADIAN SYSTEM IN 
ALZHEIMER’S DISEASE  
 
As mentioned above, key symptoms of AD include disturbed sleep (Dening & Sandilyan, 2015) 
and dysfunction of brain areas like the cholinergic system, which regulates the sleep-wake cycle 
(Hampel et al., 2018).  These factors, therefore, play integral roles in both the pathology and 
treatment of the disease.  Dysfunction of human circadian rhythms have also been correlated 
with many other disrupted health conditions, including cardiovascular disease and lung cancer, 
reflecting the importance of its role in multiple body systems (Bollinger & Schibler, 2014).  As 
Alzheimer’s Disease often co-occurs with other chronic medical conditions, the relationship 
between circadian rhythm abnormalities, sleep dysfunction, and Alzheimer’s Disease is clinically 
and socially relevant.  This interaction highlights the significance of the role of these homeostatic 
functions in the features of Alzheimer’s Disease, both individually and globally.   
 
SLEEP AND CIRCADIAN FACTORS: AN OVERVIEW 
The rhythmic oscillations of many body processes, such as metabolism, body 
temperature, and hormone secretion are endogenously generated by the circadian system in 
mammals and driven by molecular oscillators (Bollinger & Schibler, 2014).  These circadian 
rhythms, either behavioral or physiological, are clinically significant as they modulate the body’s 
activity on a twenty-four hour cycle and allow the effective use of metabolic resources without 
explicitly relying on the presence of external cues (Weaver, 2016).  However, the external light-
dark cycle plays an integral role in circadian function as it entrains the body’s endogenous 
circadian cycle, allowing for external regulation of these rhythms (Bollinger & Schibler, 2014; 
Weaver, 2016). This indicates the significance of light exposure to the sleep-wake cycle, a 
functionally important circadian rhythm.  Abnormal patterns of light exposure, seen in hospital 
or institutional settings as well as in patterns of shift work hours, therefore have the ability to 
completely disrupt the body’s circadian sleep cycle, dysregulating bodily processes and, 
likewise, affecting health outcomes (Reitz & Martino, 2015).   
The brain region considered responsible for controlling these endogenous mechanisms, 
called the brain’s master clock, is the suprachiasmatic nucleus (SCN) of the hypothalamus, 
which also happens to be anatomically located above the optic chiasm (Bollinger & Schibler, 
2014; Weaver, 2016).  This further indicates the importance of the communication between these 
brain areas for optimal circadian functioning (Weaver, 2016).  In addition, the SCN plays a role 
in regulating the rhythmic activity of peripheral oscillators throughout the body through multiple 
transcriptional-translational feedback loops, essentially allowing for the generation of complex 
and cooperative circadian rhythm control (Weaver, 2016).  The SCN, notably, is an area of 
severe degeneration in Alzheimer’s Disease (Coogan et al., 2013); thus, SCN degeneration is a 
proposed mechanism for disrupted circadian activity in AD patients, as its decreased functioning 
inhibits the effective communication of the SCN with peripheral oscillators.  As such, it is clear 
that disruptions in circadian rhythms as well as daily light exposure are relevant to Alzheimer’s 
Disease. 
Just as the circadian sleep-wake cycle is clinically relevant, the sleep cycle itself, which is 
an ultradian rhythm, likewise has health-related effects (Baghdoyan & Lydic, 2012).  While there 
is a lot of evidence underlying the neurochemical regulation of sleep and wakefulness, it is 
important to note that the explicit function of sleep is unclear and difficult to determine 
experimentally (Baghdoyan & Lydic, 2012).   Nonetheless, it is well-known that sleep is 
necessary for survival and that disturbed sleep as well as sleep deprivation are strongly 
associated with adverse health effects as well as significant cognitive impairment (Brown et al., 
2012).  The sleep cycle consists of two main phases, rapid eye movement (REM) sleep and non-
rapid eye movement (NREM) sleep, each of which is thought to play a different role in memory 
consolidation (Brown et al., 2012; Ackermann & Rasch, 2014).  While the mechanisms of 
memory consolidation during sleep are unclear, researchers know that sleep aids in the formation 
of memories (Ackermann & Rasch, 2014).  In addition, activation of cholinergic neurons is 
thought to be important for memory consolidation during REM in the elderly (Hornung et al., 
2007).  REM sleep is also associated with dreaming, indicating that dreams themselves may play 
a role in this processing (Lamberg, 2004).  This is extremely relevant for Alzheimer’s Disease 
because, as mentioned earlier, memory loss is a primary symptom of AD (Hugo & Ganguli, 
2014), and AD is strongly associated with degeneration of cholinergic neurons (Hampel et al., 
2018).  
In terms of sleep-wake cycle abnormalities, Alzheimer’s patients typically demonstrate 
increased daytime sleep and frequent awakening from nighttime sleep (Coogan et al., 2013).  
This dysregulation of the sleep-wake cycle is further exacerbated in long-term care facilities such 
as nursing homes, in which patients receive decreased exposure to natural light (Coogan et al., 
2013). In addition, it can be inferred that seasonal changes of daylight hours in some geographic 
areas may also have increasingly harmful effects.  The implications of such abnormalities are 
extensive, considering that adults ideally need seven to eight hours of healthy sleep each night 
for proper daily performance and optimal health (Watson et al., 2015). Further, researchers state 
that excessive sleep may often be as harmful as sleep deprivation in adults (Watson et al., 2015).  
Individuals with Alzheimer’s Disease, who are clearly experiencing unhealthy sleep, are thus at a 
critical health disadvantage.  To make matters worse, sleep is largely undervalued in today’s 
society, despite extensive research indicating the importance of sleep for overall mental and 
physical health.  Thus, the clinical implications of circadian dysfunction and sleep dysregulation 
ought to be emphasized even further, especially as they relate to debilitating and often fatal 
conditions such as Alzheimer’s Disease.   
 
ALZHEIMER’S DISEASE, SLEEP, AND CIRCADIAN RHYTHMS: THE PATIENT  
Every case of Alzheimer’s Disease progresses differently, as some patients die in as little 
as four years after onset while others live twenty years past their original diagnosis (Atri, 2019).  
As mentioned previously, diagnosis is often delayed (Atri, 2019). A study in China stated that 
there is a 1-2 year period between onset of symptoms and seeking out neurological treatment 
(Zhao et al., 2016).  Of course, this can be a result of many external factors such as 
socioeconomic status and education level.  Regardless of its cause, though, this latency of 
treatment can have a profound effect on patient outcomes.  The timeline is largely dependent on 
the patient as well as the presence or absence of other risk factors, many of which are affected by 
circadian rhythm dysfunction (Bollinger & Schibler, 2014).  Cardiovascular disease, a prominent 
risk factor for developing AD (Zhong et al., 2015), often results from dysfunction of circadian 
rhythms, which can be attributed to instances of myocardial infarction and even cardiac death 
(Reitz & Martino, 2015).  In addition, because circadian rhythms affect the modulation of the 
body’s response to inflammation, this system also aids in the functional and structural changes of 
the heart during recovery from myocardial infarction (Reitz & Martino, 2015).  As the 
inflammatory response is a key component of the immune system, disruptions in the immune 
system can also be associated with other health conditions beyond those associated with the 
cardiovascular system.  This role of the immune system has gained increasing attention in recent 
years, as researchers have found that the neuroinflammation that characterizes AD is a result of 
chronically activated microglia due to dysregulation of the immune response (Sarlus & Heneka, 
2017).  Additionally, it is hypothesized that this chronic activation may play a role in 
propagating aggregated tau proteins in the brain as well as disrupting neuronal signaling in the 
nervous system (Sarlus & Heneka, 2017).  Thus, this could become a more relevant target for 
treatment of AD in years to come.  
There are many other risk factors that contribute to both cardiovascular disease and 
Alzheimer’s Disease including obesity, hypertension, and diabetes mellitus (Alzheimer’s 
Association, 2016).  Diabetes mellitus patients exhibit a more rapid cognitive decline with AD, 
and abnormalities in glucose metabolism can affect the presence of amyloid plaques as well as 
brain atrophy (Shinohara & Sato, 2017).  There is a circadian component to this as well, as these 
abnormalities can be a result of misaligned feedback communication between the SCN’s 
modulation of glucocorticoid release and the peripheral oscillatory response of target endocrine 
organs (Oster et al., 2016). As discussed previously, this ineffective circadian communication 
thus adversely impacts the functioning of multiple body systems (Oster et al., 2016; Weaver, 
2016).    
Smoking status also contributes to the progression of AD, serving as a competitive death 
risk, meaning that deaths that are smoking-related may occur earlier in life and may also 
overshadow an underlying case of AD (Chang et al., 2012).  Studies have also shown that this 
survival bias may affect incidence rates of dementia because non-smoking patients generally live 
further into their elderly years when AD symptoms typically arise (Chang et al., 2012).  There is 
also a biological element to this risk, as the oxidative stress that smokers are subjected to has the 
potential to affect the presence of neurofibrillary tangles that characterize dementia (Zhong et al., 
2015).  The vascular risk associated with smoking further supports the association between 
smoking and AD (Zhong et al., 2015).  Although there are many negative side effects of tobacco 
use, studies have shown that nicotine, a nicotinic acetylcholine receptor agonist, improves 
cognitive functioning; one study demonstrates that administration of nicotine prevents the 
development of memory deficits and preserves plasticity in rodents with drug-induced AD-like 
dysfunction (Esteves et al., 2017).  As cholinergic drugs have already proven to effectively slow 
the progression of AD symptoms, there are several proposed benefits of nicotine treatment of 
AD (Esteves et al., 2017).  However, the negative side effects of nicotine use are well-known, 
and further research must be done before this could be feasible and well-regulated. 
Obstructive sleep apnea (OSA), a sleep disorder, is often comorbid with Alzheimer’s 
Disease and also associated with major AD risk factors such as cardiovascular disease and 
hypertension (Liguori et al., 2017).  However, the relationship between OSA and AD is not 
clearly defined, as both OSA and AD are common in the elderly and intimately related to 
cardiovascular health (Brzecka et al., 2018).  As a sleep disorder, OSA disrupts normal sleep and 
specifically results in increased sleep fragmentation due to increased periods of arousal with 
apneas (Brzecka et al., 2018).  For patients with OSA, hypoxia during sleep results in oxidative 
stress that, as discussed previously, has been linked to Alzheimer’s Disease (Liguori et al., 
2017).  There is a circadian factor at work here as well, as the various enzymes and antioxidants 
involved in the body’s defense response to oxidative stress exhibit circadian rhythms (Wilking et 
al., 2013).  For example, melatonin, a major sleep-promoting hormone involved in regulating the 
sleep-wake cycle and controlled by the circadian clock, has been discovered to have antioxidant 
properties as well as a role in lowering blood pressure, further indicating the complex 
relationship between circadian rhythms and the cardiovascular system (Wilking et al., 2013).  
More importantly, this also highlights the impact of the dysfunction of circadian rhythms in AD, 
as the oxidative stress and metabolic dysregulation that results from OSA have been associated 
with the promotion of the neurological degeneration and cognitive impairment seen in AD 
(Liguori et al., 2017; Brzecka et al., 2018).   
Sleep hygiene, which involves modifiable behaviors such as restricting time in bed, 
limiting caffeine and alcohol intake, and establishing a dark and quiet sleep environment, is 
important for optimal sleep and, therefore, overall health (Homolak et al., 2018).  Poor sleep 
hygiene is frequently seen in AD patients, as these elderly individuals naturally have more 
unstructured daily schedules and spend more time in bed; in addition, the atmosphere of nursing 
homes is normally fairly loud, patients are often exposed to bright light during the night, and 
sleep is often disrupted by nighttime monitoring by staff (Homolak et al., 2018).   While it is true 
that Alzheimer’s Disease is characterized by internally driven sleep abnormalities and 
dysfunction of the sleep-wake cycle, sleep quality is often further reduced due to the poor sleep 
hygiene of AD patients (Bollinger & Schibler, 2014; Dening & Sandilyan, 2015).   
 Thus, it becomes explicitly clear that there is a complex relationship between all of these 
variables: while the development of several major AD risk factors is strongly associated with 
circadian rhythm dysfunction and reduced sleep quality, these abnormalities are also considered 
symptoms of Alzheimer’s Disease itself.  In addition, many commonly used medications for 
conditions like hypertension and diabetes disrupt the normal sleep cycle, so it must be considered 
that any sleep abnormalities AD patients experience could be secondary to or exacerbated by 
these medications (Naiman, 2017).  The presence of these interconnected relationships is a key 
component of the complexity of Alzheimer’s Disease and indicates that many of the risk factors 
associated with AD may also impact its progression due to the effects of circadian disruptions 
and decreased sleep quality on these preexisting health conditions.  In addition, this deleterious 
cycle, with many factors negatively affecting overall health, may also contribute to the timing 
and cause of death in AD patients.   
Health risks aside, the progression of AD undoubtedly has a profound effect on quality of 
life of the patient.  One particular study shows that patient interactions with strong networks of 
friends is correlated with improved cognitive ability (Balouch et al., 2019). Studies have also 
shown that groups of elderly females who regularly participate in social activities have a lower 
incidence of developing dementia (Hugo & Ganguli, 2014).  However, this is undoubtedly a 
bidirectional relationship, as a decline in cognition may also result in fewer social interactions 
with friends (Balouch et al., 2019).  Additionally, patients with dementia are often socially 
isolated, which can either be a cause or effect of depression and loneliness in dementia patients 
(Sun et al., 2019).  They also experience changes in the ways they engage with their interests, 
especially in terms of hobbies or exercise (Atri, 2019).  While this may be a result of memory 
loss, a trend toward isolation is largely to blame, as the nature of the patient’s self-confidence is 
diminished with dementia (Atri, 2019).  Of course, this may be attributed to a patient’s living 
accommodations as well as a decreased sense of independence and autonomy (Sun et al., 2019).  
Thus, mental health is extremely relevant for the treatment of patients battling Alzheimer’s 
Disease, as cognitive impairment and decline in mental health are very much related.  This is 
coupled with the fact that many Alzheimer’s Disease patients are largely unaware of the 
functional difficulties they are experiencing with daily tasks, and they frequently attribute any 
awareness of cognitive decline to other external factors rather than labeling them as symptoms of 
Alzheimer’s Disease (Emery et al., 2018).  Agitation is also often a symptom of AD, which 
impacts patients’ overall quality of life as it may potentially create tension in the home 
(Senanarong et al., 2004).  Psychiatric disorders such as post-traumatic stress disorder, anxiety, 
and depression are also considered risk factors of dementia, further indicating a bidirectional 
relationship between mental health and development of AD (Hugo & Ganguli, 2014).  Thus, as a 
complex and degenerative cognitive disease, the mental health symptoms afflicting these patients 
are likewise multifactorial.     
 
ALZHEIMER’S DISEASE, SLEEP, AND CIRCADIAN RHYTHMS: THE 
FAMILY/CAREGIVER  
 Patients, especially those in the later stages of the disease, will generally live in a nursing 
home or with a full time family caregiver (Lane et al., 2018).  This is largely because of the 
difficulty of implementing patient-centered care in a hospital setting, where the focus is on short 
term stays due to the increased risk of urinary tract infection, pneumonia, and other illnesses in 
AD patients with extended stays (Toye et al., 2019).  As patients develop a state of complete 
dependence, the role of the caregiver thus becomes increasingly important for daily functioning 
of the patient.  Quality of life is a priority for the continuity of care of AD patients, and the 
impression of a patient’s overall quality of life is generally very different for the family and 
health care staff, as education level as well as personal relationship with the patient largely affect 
their opinions (Robertson et al., 2019).  Nonetheless, the role of the family is vital to the 
experience of the patient, as effective communication with health care staff is best achieved via 
family caregivers who have a close relationship with the patient as well as knowledge of the 
patient’s medical history and baseline functioning (Toye et al., 2019).   
As a result, there is a heavy responsibility and burden placed on caregivers, which has 
become a significant topic of discussion in the patient care aspects of treating neurodegenerative 
disorders such as AD.   While many caregiver tasks largely involve assistance and guidance with 
daily tasks, the work required of family caregivers requires much sacrifice and far exceeds the 
normal expectations of daily living (Seaman, 2018).  It is common for caregivers of AD patients 
to experience increased stress and anxiety as a result of the emotional burden of their roles, and 
there is evidence supporting the need for those treating AD patients to better consider the effects 
of treatment on the caregiver, as this ultimately impacts outcomes for patients themselves 
(Savundranayaham et al., 2010).  Further, the emotional stress can lead caregivers to become 
more focused on the inevitable health outcomes of AD, adopting complacent attitudes and 
believing that their intervention does not affect the end result (Seaman, 2018).  In addition, the 
sleep fragmentation and circadian disturbances experienced by AD patients affects caregivers as 
well, which can also impact their health, affecting their ability and potentially even their 
willingness to care for the patient in the home (Homolak et al., 2018).  This makes the decision 
of caring for AD patients in the home versus arranging care in nursing homes much more 
complicated, as there are conflicting viewpoints about the best routes for achieving the highest 
levels of patient care, including the effectiveness and ethicality of institutionalization.   
 
ALZHEIMER’S DISEASE: TREATMENT AND PREVENTION 
 As Alzheimer’s is currently incurable, treatments are aimed at symptoms of the disease 
and slowing its progression rather than reducing or eliminating the neurological damage 
associated with AD (Lane et al., 2018).  Effective treatment and management of AD goes beyond 
the patient and physician, involving the patient’s family members, caregivers, etc. (Atri, 2019). 
Additionally, providers must pay particular attention to regulating psychiatric and behavioral 
symptoms through regular psychiatric screening as well as regular education of both the patient 
and the caregiver of the appropriate expectations regarding progression of the disease (Atri, 
2019).   
 In recent years, there has been increasing support for the use of music therapy in 
management of cognitive decline in Alzheimer’s Disease, especially considering the role of these 
sensory cues in involuntary memory recall (Leggieri et al., 2019).  Morning light therapy has 
also been shown to have a significant effect on the stabilization of circadian rhythm 
abnormalities in AD patients (Coogan et al., 2013).  However, a more interventional approach 
for symptomatic regulation is a main focus of managing Alzheimer’s Disease.  As mentioned 
previously, cholinesterase inhibitors are a common and effective medication used for 
Alzheimer’s treatment (Hugo & Ganguli, 2014).  These medications effectively inhibit the 
breakdown of acetylcholine in an effort to counter the effects of degeneration of cholinergic 
neurons in AD patients (Atri, 2019).  Acetylcholine is an excitatory neurotransmitter in the brain 
that helps regulate the sleep-wake cycle as well as aid in learning, memory, and attention 
(Baghdoyan & Lydic, 2012).  Thus, enhancing the role of this neurotransmitter is indicated for 
partial improvement of symptoms such as cognitive decline; however, it must be noted that these 
symptoms are not reversed by any of the AD medications used today (Lane et al., 2018).   There 
are limited options for pharmacological management of Alzheimer’s Disease, largely due to the 
cost of engineering new drugs and the lengthy process of determining the overall effect on the 
patient (Lane et al., 2018). As AD is strongly related to cardiovascular disease and other chronic 
medical conditions (Bollinger & Schibler, 2014), drug interactions must also be considered when 
planning a course of Alzheimer’s treatment, both for regulating other chronic health conditions 
and managing AD symptoms (Atri, 2019).  In my opinion, though, the most important factor of 
AD treatment involves the principle that any interventions or conversations should be carried out 
with the patient in mind, with modifications based on progression of the disease, as the patient’s 
ability to engage in discussions about his/her care may be diminished as the disease progresses.  
In terms of preventative approaches for Alzheimer’s Disease, exercise is cited as a 
prospective method for prevention, notably for those at risk for AD (Cass, 2017).  It has also 
been proposed that regular exercise could also potentially be effective for management of MCI 
as well as AD (Ströhle et al., 2015).   In my opinion, this may be due to the more generalized 
beneficial health effects of regular exercise on cardiovascular health, etc.  However, the 
relationship between exercise and cognition should not be ignored, as studies have shown that 
cognitive functioning is improved by exercise in non-AD subjects (Smith et al., 2010).  One 
study also shows that exercise aids in the regulation of circadian rhythms in elderly individuals, 
so this could be a possible mechanism for the benefits of exercise for the prevention and 
management of AD (Van Someren et al., 1997).  Further, the time of day may also impact the 
effect of exercise on the circadian system.  Another study highlights that the effects of exercise 
and light exposure on circadian rhythms may be synergistic, so outdoor exercise could even 
enhance the effects of exercise on regulating circadian rhythms (Barger et al., 2004).  Of course, 
these behaviors will impact the sleep-wake cycle as well, so the effects of these 
nonpharmacological interventions may surely be additive.  In addition to the role of physical 
exercise, studies have shown that a generally healthy and active lifestyle in which persons have 
regular cognitive exercise can be very preventative in terms of cognitive impairment and AD 




CONCLUSION: WHAT NOW?  
 While Alzheimer’s Disease researchers have not been successful in finding a cure, it is 
important to note that the is a great deal that has yet to be discovered about the human brain.  
Treatment methods are still being developed and modified, and there is much to look forward to 
for the future of Alzheimer’s Disease research.  While pharmacologic treatments are a standard 
and effective form of treatment of AD symptoms, I argue for a more unconventional focus 
looking forward.  The profound role of circadian rhythms as well as sleep quality indicates a 
need for treatment approaches to better manage and regulate patients’ sleep-wake cycles as well 
as the activity of their entire circadian system.  As demonstrated throughout this paper, these 
factors are intimately related to Alzheimer’s Disease as well as many other diseases that are 
comorbid with AD.  While this nonpharmaceutical approach may not be the most effective form 
of treatment on its own, treatment ought to be more concentrated on factors such as the effects of 
behavioral management, light exposure, quality of home life, caregiver wellbeing, sleep hygiene, 
etc.  In addition, as cost-effective treatments are difficult to develop, this holistic approach to 
detection and treatment of AD and AD-like disorders may likely be one of the more effective 
approaches for preventive medicine, both in terms of prevention of the disease itself and 
prevention of its rapid progression.   
Adopting a more holistic approach to treatment may pose several challenges, though, 
particularly because it is difficult to prove that any causal relationship exists between certain 
circadian and sleep-related factors and Alzheimer’s Disease.  As the brain is a complex organ, 
any correlations must not be overstated, but they should be considered.  However, it is possible 
that patients and their loved ones may be less supportive of some nonpharmacologic treatments, 
especially because these outcomes are extremely variable for each individual.  Nonetheless, it 
should become standard for important behavioral and environmental factors such as light 
exposure, sleep hygiene, and exercise to be included in patient care, particularly in nursing home 
facilities where these factors can be effectively monitored. 
While there is no clear solution to the problem of Alzheimer’s Disease, these 
modifications of existing treatment methods could improve quality of life of the patient, if 
nothing else.  Of course, more research is also needed in many areas, including the extent of the 
role of the immune system in Alzheimer’s Disease.  Most importantly, though, engaging the 
public in the conversation about Alzheimer’s Disease and treatment options is essential for 
improving early detection and management of AD.  This also includes spreading awareness by 
encouraging society to value the importance of certain unappreciated factors such as sleep in 
regard to their overall health as well as the management of existing health conditions.  It is 
important to note, however, that the goal of this focus is not a cure.  Rather, it offers new 
direction that may unlock the potential for better management of Alzheimer’s Disease and 
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